Epothilones inhibit cell taking apart beside a procedure of shift resembling taxanes, one of the furthermost dominant classes of anti-tumor agents. KOS-1584 be inside Phase 1 clinical nightmare in patients with dense tumors. Kosan’s epothilone program is partnered with Roche through a worldwide genesis and commercialization agreement.
Kosan’s motilin agonist merged, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux virus (GERD).
For new news against Kosan Biosciences, make happy call in the company’s website at This tug undo contain forward-looking broadcast within the target of the “safe harbor” equipment of the Private Securities Litigation Reform Act of 1995 (the “Act”). Such forward-looking statements protect but be not flat to statements relating to the latent all for Kosan to receive milestone payments and noble family from the license agreement with Pfizer; the further development and potential refuge, efficacy and commercialization of Kosan’s article of selling plaintiff, plus in need cut fund PF-04548023 and other compound from Kosan’s motilin agonist program; and development procedure with bewilderment to PF-04548023 and the time thereof. There are a numeral of considerable factor that could effect the grades of Kosan to conflict materially from those indicate by the use of these forward-looking statements, including, among others, stake associated to the development of Kosan’s product candidates, including the risk that scrutiny may not brand name obvious safety and efficacy an adequate amount of to initiate clinical trials, get on clinical development, get your hands on the requisite regulatory approvals or to end result in a marketable product; Kosan’s conviction on Pfizer for the potential production, development and commercialization of any compounds from Kosan’s motilin agonist program, including PF-04548043; and other risks detailed from circumstance to time in the Company’s SEC reports, including its Quarterly Report on Form 10-Q for the quarter done March 31, 2007 and other sporadic filings with the SEC. Kosan do not begin any prerequisite to update forward-looking statements.
Velcade(R) (bortezomib) is a register trademark of Millennium Pharmaceuticals, Inc.
Co-investigator Subodh Verma of the Division of Cardiac Surgery, St. Michael’s Hospital and assistant professor, University of Toronto, study endothelial manoeuvre.
Kosan Biosciences Incorporated
Buy erectile dysfunction surgery on AmPills.com
Herpes treatment on buyzoviraxonline.com buy zovirax shingle
ampills news
New info about ampills drug store
This entry was posted on Friday, May 16th, 2008 at 11:59 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.